- ISIN
- US76200L3096
- CUSIP
- 76200L309
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 1, 2014
Highlights
- Market Cap
- $454.50M
- Enterprise Value
- $445.05M
- EPS (TTM)
- -$0.79
- Gross Profit (TTM)
- -$15.00K
- EBITDA (TTM)
- -$67.00M
- Year Range
- $1.07 - $11.46
- Target Price
- $6.33
- ROA (TTM)
- -64.95%
- ROE (TTM)
- -69.74%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $6.97M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RZLT Performance Chart
Rezolute, Inc. (RZLT) is up 100.0% since the beginning of the year. At $5 per share, RZLT is trading 58.8% below its 52-week high of $11. Investors who bought $1,000 worth of RZLT shares 5 years ago would now be looking at an investment worth $424.
Loading charts...
Compare this symbol against anything
Returns By Period
Rezolute, Inc. (RZLT) has returned 100.00% so far this year and -19.59% over the past 12 months. Over the last ten years, RZLT has returned -20.19% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Rezolute, Inc.
- 1D
- -3.28%
- 1M
- -3.87%
- 6M
- 41.32%
- YTD
- 100.00%
- 1Y
- -19.59%
- 3Y*
- 38.67%
- 5Y*
- -15.77%
- 10Y*
- -20.19%
- ALL TIME*
- -26.35%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RZLT Monthly Returns History
Based on dividend-adjusted daily data since May 1, 2014, RZLT's average daily return is +0.33%, while the average monthly return is +2.00%. At this rate, an investment would double in approximately 2.9 years.
Historically, 43% of months were positive and 57% were negative. The best month was Jul 2020 with a return of +269.9%, while the worst month was Dec 2025 at -75.7%. The longest winning streak lasted 11 consecutive months, and the longest losing streak was 8 months.
On a daily basis, RZLT closed higher 36% of trading days. The best single day was Jan 7, 2019 with a return of +250.0%, while the worst single day was Dec 11, 2025 at -87.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 41.53% | -3.89% | -4.98% | 4.92% | 3.12% | 57.58% | -9.23% | 100.00% | |||||
| 2025 | 7.14% | -15.62% | -34.54% | 29.66% | 9.57% | 8.25% | 33.41% | 19.66% | 32.02% | -0.85% | 4.29% | -75.72% | -51.84% |
| 2024 | 10.83% | 50.00% | 54.55% | 5.10% | 50.37% | 6.70% | 6.86% | 3.59% | 1.89% | 12.99% | -8.03% | -2.78% | 393.70% |
| 2023 | 24.15% | -3.50% | -22.58% | 8.59% | 2.16% | -7.04% | -5.56% | -22.99% | -8.33% | -28.03% | -18.74% | 28.56% | -52.05% |
| 2022 | -4.60% | -42.76% | 29.50% | 12.43% | -26.32% | 15.36% | -3.10% | -23.96% | 15.13% | -38.32% | -2.37% | 25.45% | -56.69% |
| 2021 | 33.19% | -27.99% | -38.61% | -5.10% | 54.18% | 38.14% | -21.97% | -17.02% | -19.06% | -14.42% | -20.63% | -5.91% | -60.13% |
Benchmark Metrics
Rezolute, Inc. has an annualized alpha of 114.69%, beta of 0.56, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since May 01, 2014.
- This stock participated in 218.19% of S&P 500 Index downside but only 57.75% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.56 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 114.69%
- Beta
- 0.56
- R²
- 0.00
- Upside Capture
- 57.75%
- Downside Capture
- 218.19%
Return for Risk
Risk / Return Rank
RZLT ranks 52 for risk / return — above 52% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Rezolute, Inc. (RZLT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RZLT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.58 | ||
| Sortino ratioReturn per unit of downside risk | -0.61 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.25 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | -0.24 | 2.00 | -2.24 |
| Martin ratioReturn relative to average drawdown | -0.38 | 8.49 | -8.87 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rezolute, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rezolute, Inc. was 99.63%, occurring on Nov 29, 2023. The portfolio has not yet recovered.
The current Rezolute, Inc. drawdown is 97.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.63%Nov 2023 | 9y 7mo | — | 12y 3moMay 2014 - now | — |
Drawdown Indicators
| RZLT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.63% | -56.78% | -42.85% |
Max Drawdown (1Y)Largest decline over 1 year | -87.20% | -9.10% | -78.10% |
Max Drawdown (3Y)Largest decline over 3 years | -87.20% | -18.90% | -68.30% |
Max Drawdown (5Y)Largest decline over 5 years | -93.50% | -25.43% | -68.07% |
Max Drawdown (10Y)Largest decline over 10 years | -99.16% | -33.92% | -65.24% |
Current DrawdownCurrent decline from peak | -97.64% | -1.58% | -96.06% |
Average DrawdownAverage peak-to-trough decline | -87.13% | -10.70% | -76.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.84% | 2.14% | +52.70% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Rezolute, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Rezolute, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RZLT in comparison with other companies in the Biotechnology industry. Currently, RZLT has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RZLT
Add Rezolute, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RZLT